Ítem
Solo Metadatos

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

Mostrar el registro sencillo de la publicación
dc.creatorGottenberg, J-Espa
dc.creatorGuillevin, Lspa
dc.creatorLambotte, Ospa
dc.creatorCombe, Bspa
dc.creatorAnaya, Juan-Manuelspa
dc.date.accessioned2020-08-19T14:41:03Z
dc.date.available2020-08-19T14:41:03Z
dc.date.created2004-11-14spa
dc.description.abstractObjective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjo¨gren’s syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttp://dx.doi.org/10.1136/ard.2004.029694
dc.identifier.issnISSN: 0003-4967
dc.identifier.issnEISSN: 1468-2060
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/27119
dc.language.isoengspa
dc.publisherEuropean League Against Rheumatismspa
dc.publisherBMJ Publishingspa
dc.relation.citationEndPage920
dc.relation.citationIssueNo. 6
dc.relation.citationStartPage913
dc.relation.citationTitleAnnals of the Rheumatic Diseases
dc.relation.citationVolumeVol. 64
dc.relation.ispartofAnnals of the Rheumatic Diseases, ISSN: 0003-4967;EISSN: 1468-2060, Vol.64, No.6 (Jun 2005); pp. 913-920spa
dc.relation.urihttps://ard.bmj.com/content/annrheumdis/64/6/913.full.pdfspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.sourceAnnals of the Rheumatic Diseasesspa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subject.keywordLupus erythematosusspa
dc.subject.keywordsystemicspa
dc.subject.keywordDrug therapyspa
dc.subject.keywordRheumatic diseasesspa
dc.subject.keywordSjogren's syndromespa
dc.titleTolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseasesspa
dc.title.TranslatedTitleTolerancia y eficacia a corto plazo de rituximab en 43 pacientes con enfermedades autoinmunes sistémicasspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos